Interleukin-3-mediated regulation of beta-catenin in myeloid transformation and acute myeloid leukemia
- Author(s)
- Sadras, T; Perugini, M; Kok, CH; Iarossi, DG; Heatley, SL; Brumatti, G; Samuel, MS; To, LB; Lewis, ID; Lopez, AF; Ekert, PG; Ramshaw, HS; D'Andrea, RJ;
- Details
- Publication Year 2014-07,Volume 96,Issue #1,Page 83-91
- Journal Title
- J Leukoc Biol
- Publication Type
- Journal Article
- Abstract
- Aberrant activation of beta-catenin is a common event in AML and is an independent predictor of poor prognosis. Although increased beta-catenin signaling in AML has been associated with oncogenic translocation products and activating mutations in the FLT3R, the mechanisms that activate beta-catenin in AML more broadly are still unclear. Here, we describe a novel link between IL-3 signaling and the regulation of beta-catenin in myeloid transformation and AML. In a murine model of HoxB8 and IL-3 cooperation, we show that beta-catenin protein levels are modulated by IL-3 and that Cre-induced deletion of beta-catenin abolishes IL-3-dependent growth and colony formation. In IL-3-dependent leukemic TF-1.8 cells, we observed increased beta-catenin protein levels and nuclear localization in response to IL-3, and this correlated with transcriptional induction of beta-catenin target genes. Furthermore, IL-3 promoted beta-catenin accumulation in a subset of AML patient samples, and gene-expression profiling of these cells revealed induction of WNT/beta-catenin and TCF4 gene signatures in an IL-3-dependent manner. This study is the first to link beta-catenin activation to IL-3 and suggests that targeting IL-3 signaling may be an effective approach for the inhibition of beta-catenin activity in some patients with AML.
- Publisher
- Society for Leukocyte Biology
- Research Division(s)
- Cell Signalling And Cell Death
- Publisher's Version
- https://doi.org/10.1189/jlb.2AB1013-559R
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2014-09-15 12:08:27